Building a collaborative approach to patient-centric artificial intelligence initiatives

Mati Gill, AION Labs CEO, provides an update on the company’s nine AI-enabled drug discovery portfolio companies, how the organizations are making an impact in life sciences and what’s next for AION, including exploring quantum technologies.

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.

Surgeon and futurist Dr. Shafi Ahmed talks about how AI is shaping healthcare's future, including its use in digital surgery, drug development, wearables, genomic medicine and clinical decision support.